MeiraGTx Holdings plc
MeiraGTx Holdings plc is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is Next quarterly earnings (projected) on November 12, 2026, a projected date rather than a confirmed one. There are 4 upcoming events on record.
MeiraGTx Holdings plc generates cash from operations, so a burn-based runway figure does not apply.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 12, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| June 30, 2027 | A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa | Trial Milestone | Phase 3 |
| September 20, 2029 | Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene | Trial Milestone | Phase 3 |
| October 24, 2030 | A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP) | Trial Milestone | Phase 2 |
Track MGTX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open MGTX in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.